Could a single eye implant replace years of glaucoma drops?

NCT ID NCT07036510

Recruiting now Disease control Sponsor: EyeD Pharma Source: ClinicalTrials.gov ↗

First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This trial tests a new implant that slowly releases the glaucoma drug timolol inside the eye. It is for people with open-angle glaucoma or ocular hypertension who are already having cataract surgery. The study compares three doses of the implant against standard timolol eye drops to see if the implant can safely lower eye pressure for up to three years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: a timolol-releasing intraocular implant (TimoD) and timolol eye drops
What this could lead to: If it works, this implant could offer a more convenient way to lower eye pressure for years with a single procedure, reducing the need for daily eye drops.
What could go wrong: This is an early feasibility study with only 42 participants, so safety and effectiveness are not yet proven. The implant requires eye surgery, which carries risks like infection or inflammation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLAUCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cataract glaucoma lens disorder ocular hypertension open-angle glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLAUCOMA OCULAR HYPERTENSION

Contacts and locations

Locations

Panama Eye Center
RECRUITING

Panama City, Panama

More trials for these conditions

Other studies related to the condition(s) this trial covers.